Tidal Investments LLC Has $1.66 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Tidal Investments LLC grew its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 142.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,149 shares of the biotechnology company's stock after purchasing an additional 6,558 shares during the quarter. Tidal Investments LLC's holdings in Repligen were worth $1,659,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. First Turn Management LLC bought a new position in shares of Repligen during the third quarter worth about $13,202,000. Geneva Capital Management LLC raised its holdings in shares of Repligen by 8.5% in the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock valued at $20,638,000 after purchasing an additional 10,908 shares during the last quarter. Banque Pictet & Cie SA lifted its position in shares of Repligen by 74.6% in the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company's stock worth $4,351,000 after purchasing an additional 14,746 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock worth $75,866,000 after purchasing an additional 425,061 shares during the last quarter. Finally, Integral Health Asset Management LLC grew its position in Repligen by 20.0% in the second quarter. Integral Health Asset Management LLC now owns 60,000 shares of the biotechnology company's stock valued at $7,564,000 after purchasing an additional 10,000 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on RGEN shares. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday. They set a "hold" rating and a $165.00 price objective for the company. Wells Fargo & Company began coverage on Repligen in a research note on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective on the stock. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday. They issued a "hold" rating and a $165.00 target price for the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Finally, Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating on the stock. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $185.20.

Repligen Stock Performance

RGEN traded down $10.80 during trading on Wednesday, hitting $147.34. The stock had a trading volume of 573,665 shares, compared to its average volume of 655,454. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a 50 day moving average price of $143.61 and a 200-day moving average price of $141.74. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The firm has a market cap of $8.26 billion, a price-to-earnings ratio of -398.21, a P/E/G ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. During the same quarter in the previous year, the business posted $0.23 earnings per share. Repligen's quarterly revenue was up 9.7% on a year-over-year basis. As a group, research analysts predict that Repligen Co. will post 1.54 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.